ArticleAME case reports2025
"Not-So-Indolent" neuroendocrine neoplasms: two case reports of gastrointestinal small cell neuroendocrine carcinomas.
Article in AME case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small cell neuroendocrine carcinomas (SCNECs) of the gastrointestinal (GI) tract are exceedingly rare and aggressive malignancies. Unlike pulmonary SCNECs, which are well-characterized, extrapulmonary GI-SCNECs lack established diagnostic pathways and treatment algorithms due to their rarity and histopathological overlap with other poorly differentiated tumors. Literature on their clinical course remains limited to isolated reports, with scarce data on site-specific presentations. These two cases contribute to the existing literature by illustrating distinct primary GI sites (gastric and rectal), underscoring the challenges in early diagnosis and the aggressive clinical progression despite intervention. Case Description: The first patient, an 80-year-old man, presented with progressive dysphagia and dyspnea. Imaging revealed mediastinal lymphadenopathy and gastric wall thickening. Endoscopic biopsies confirmed gastric SCNEC with widespread metastases. Despite initiation of palliative care, his condition deteriorated rapidly, and he died one month after diagnosis. The second patient, a 69-year-old man, presented with significant weight loss and lower abdominal pain. Colonoscopy identified a circumferential rectal mass, and biopsies confirmed SCNEC. Staging demonstrated hepatic and nodal metastases. He received platinum-based chemotherapy and pelvic radiotherapy, achieving only transient stabilization. Following treatment cessation, his disease progressed, and despite resuming chemotherapy, he died 11 months after diagnosis. Conclusions: These cases emphasize the necessity for heightened clinical suspicion of SCNEC in rapidly progressive GI malignancies, even in atypical presentations. Early recognition and multidisciplinary management are crucial, although current therapeutic options offer limited durability. By delineating site-specific clinical courses, this report contributes to the limited body of evidence on GI-SCNECs and underscores the urgent need for standardized diagnostic criteria and treatment protocols to improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.